Shionogi & Co., Ltd company information, Employees & Contact Information

Shionogi & Co. Announces Merger with Shionogi Pharma to Strengthen Supply Chain TipRanks

Shionogi & Co (4507 JP): Muted 1H Result; Solid HIV Business Leads FY Profit Guidance Raise Smartkarma

Shionogi & Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2025, Payable on December 01, 2025 MarketScreener

Shionogi & Co. Reports Q2 2025 Financial Results and Strategic Expansion TipRanks

Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion Reuters

Shionogi Implements Stibo Systems MDM Solution PR Newswire

Shionogi to acquire Japan Tobacco pharma companies for $1.1B BioWorld MedTech

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary The Globe and Mail

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations Business Wire

Notice of Head Office Relocation｜ 塩野義製薬 Shionogi Inc.

Shionogi & Co. Adopts New Management Policies to Enhance Capital and Stock Awareness TipRanks

History Shionogi Inc.

Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants BioWorld MedTech

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary TipRanks

Japan to grant emergency approval to Shinogi COVID-19 drug Reuters

What we stand for: Takeki Uehara | Clinical Development Vision and Strategy | Shionogi & Co., Ltd. Shionogi Inc.

Shionogi to Acquire Japan Tobacco’s Pharmaceutical Business TipRanks

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aimed at maximizing value Shionogi Inc.

Message from Top Management Shionogi Inc.

Investigator-Initiated ResearchR&D｜Innovation｜Shionogi Co., Ltd. Shionogi Inc.

Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission Reuters

Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial Reuters

Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan GlobeNewswire

Japan to consider early approval for Shionogi COVID pill Reuters

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir ACS Publications

Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma Bloomberg.com

Shionogi & Co. (SGIOY) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance

Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, phase 2 clinical trial - Kato - 2023 - Psychiatry and Clinical Neurosciences Wiley Online Library

Shionogi’s oral COVID-19 antiviral wins full approval in Japan BioWorld MedTech

Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections Business Wire

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals GSK

Involvement of the vagus nerve in the anorectic effect of monoacylglycerol acyltransferase 2 inhibition in mice Wiley Online Library

Shionogi’s COVID-19 drug misses endpoint in global phase III BioWorld MedTech

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan The AI Journal

Shionogi Covid Pill Xocova Fails to Win Japan’s Panel Backing Bloomberg.com

Shionogi’s FETROJA® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S. Business Wire

“Gamma Wave Sound” jointly developed by Pixie Dust Technologies, Inc. and Shionogi & Co., Ltd. won the ACC TOKYO CREATIVITY AWARDS for Creative Innovation Gold and ICC Summit Award Pixie Dust Technologies

“Defy Dementia with Sound.” Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamma Wave Sound to boost everyday cognitive care. Business Wire

Shionogi COVID-19 pill Xocova wins emergency approval in Japan The Japan Times

“kikippa,” a TV speaker for listening to gamma wave sound in daily life, will be on sale from Tuesday, April 18th. ~Making elderly people’s lives more comfortable with gamma wave modulation technology Pixie Dust Technologies

Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017 PR Newswire

Pixie Dust Technologies Announced its Gamma Wave Modulated “kikippa” Speakers is Now Available at 10 Bic Camera Stores and Online Bic Camera, Kojima, and Sofmap Sites Pixie Dust Technologies

Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder Wiley Online Library

COVID-19 pill sales could hit $2 billion, drugmaker Shionogi says The Japan Times

Shionogi Inks Deal to Acquire Victory Pharma Pharmacy Times